Realta Investment Advisors Makes New Investment in Aflac Incorporated (NYSE:AFL)

Realta Investment Advisors purchased a new position in Aflac Incorporated (NYSE:AFLFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,799 shares of the financial services provider’s stock, valued at approximately $231,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AFL. Panagora Asset Management Inc. boosted its holdings in shares of Aflac by 36.2% during the 1st quarter. Panagora Asset Management Inc. now owns 23,941 shares of the financial services provider’s stock worth $1,542,000 after purchasing an additional 6,369 shares during the last quarter. Blair William & Co. IL lifted its position in Aflac by 6.8% during the first quarter. Blair William & Co. IL now owns 17,268 shares of the financial services provider’s stock worth $1,112,000 after buying an additional 1,102 shares in the last quarter. Aviva PLC lifted its position in Aflac by 0.7% during the first quarter. Aviva PLC now owns 210,634 shares of the financial services provider’s stock worth $13,563,000 after buying an additional 1,503 shares in the last quarter. Dakota Wealth Management acquired a new position in Aflac during the first quarter worth $428,000. Finally, Sequoia Financial Advisors LLC grew its holdings in Aflac by 7.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 6,142 shares of the financial services provider’s stock valued at $396,000 after buying an additional 417 shares in the last quarter. 67.44% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Thomas J. Kenny sold 5,000 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total value of $423,100.00. Following the sale, the director now directly owns 17,920 shares in the company, valued at $1,516,390.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Masatoshi Koide sold 30,493 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the completion of the transaction, the director now directly owns 86,090 shares of the company’s stock, valued at $6,879,451.90. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Thomas J. Kenny sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $84.62, for a total transaction of $423,100.00. Following the completion of the sale, the director now directly owns 17,920 shares in the company, valued at approximately $1,516,390.40. The disclosure for this sale can be found here. Insiders sold a total of 46,493 shares of company stock worth $3,765,706 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Aflac Stock Performance

Shares of Aflac stock opened at $85.19 on Tuesday. The stock has a market capitalization of $49.02 billion, a price-to-earnings ratio of 10.99, a price-to-earnings-growth ratio of 2.35 and a beta of 0.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.06 and a quick ratio of 0.06. The business has a 50-day moving average of $81.79 and a 200 day moving average of $80.94. Aflac Incorporated has a 12 month low of $63.08 and a 12 month high of $86.26.

Aflac (NYSE:AFLGet Free Report) last posted its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing the consensus estimate of $1.47 by ($0.22). Aflac had a net margin of 24.92% and a return on equity of 17.59%. The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $4.44 billion. During the same period in the previous year, the business posted $1.29 EPS. As a group, sell-side analysts forecast that Aflac Incorporated will post 6.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. StockNews.com raised shares of Aflac from a “sell” rating to a “hold” rating in a research report on Thursday, March 28th. Raymond James increased their price target on shares of Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Wells Fargo & Company lifted their price target on shares of Aflac from $82.00 to $83.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 6th. Evercore ISI lowered Aflac from an “in-line” rating to an “underperform” rating and increased their price objective for the stock from $76.00 to $78.00 in a research report on Thursday, January 4th. Finally, UBS Group lifted their target price on Aflac from $80.00 to $84.00 and gave the company a “neutral” rating in a research report on Wednesday, January 10th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $80.36.

Check Out Our Latest Research Report on Aflac

Aflac Company Profile

(Free Report)

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.

Featured Stories

Institutional Ownership by Quarter for Aflac (NYSE:AFL)

Receive News & Ratings for Aflac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac and related companies with MarketBeat.com's FREE daily email newsletter.